Cohance Lifesciences Net Down 21% In March Quarter; Revenue Jumps 59%

Cohance Lifesciences Ltd.'s consolidated net profit for the March quarter fell 21.3% on year to ₹420.1 million, even as revenue from operations surged 58.9% to ₹4.02 billion. Sequentially, net profit slumped 49.3%, while revenue rose 30.9%.

Other income dropped to ₹105.7 million from ₹170.6 million a year ago.

Total expenditure, including finance costs, more than doubled on year to ₹3.61 billion in the quarter. Finance cost jumped over twofold to ₹57.5 million. Tax outgo stood at ₹128.7 million, down from ₹174.8 million a year earlier.

For 2024-2025, net profit declined 10.8% to ₹2.68 billion, while revenue rose 13.9% to ₹11.98 billion.